Personalis and Tempus Expand Collaboration to Biopharma
Personalis, Inc. (PSNL)
Last personalis, inc. earnings: 3/25 04:01 pm
Check Earnings Report
Company Research
Source: Business Wire
Expanded collaboration to yield greater biopharma access to Personalis’ MRD solution FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus is serving as the exclusive commercial diagnostic partner for Personalis’ ultra-sensitive tumor-informed MRD product, NeXT Personal® Dx, for broad patient adoption in breast and lung cancers, and for immunotherapy monitoring across all solid tumors.Following a positive reaction from the diagnostic market, the companies have agreed to expand their relationship to the biopharma industry. Under this expanded relationship, Tempus will be enabled to offer Personalis’ NeXT Personal MRD product to pharmaceutical and biotech
Show less
Read more
Impact Snapshot
Event Time:
PSNL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PSNL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PSNL alerts
High impacting Personalis, Inc. news events
Weekly update
A roundup of the hottest topics
PSNL
News
- Personalis, Inc. (NASDAQ: PSNL) had its price target raised by analysts at HC Wainwright from $9.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Personalis, Inc. (NASDAQ: PSNL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $7.25 price target on the stock.MarketBeat
- Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna [Yahoo! Finance]Yahoo! Finance
- Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with ModernaBusiness Wire
- Personalis and Tempus Expand Collaboration to Biopharma [Yahoo! Finance]Yahoo! Finance
PSNL
Earnings
- 11/6/24 - Miss
PSNL
Sec Filings
- 12/19/24 - Form 8-K
- 12/18/24 - Form 4
- 12/18/24 - Form 4
- PSNL's page on the SEC website